About Our Team
Helping to improve patient care and outcomes
with products that provide early and specific
insights into clinical conditions.
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is a significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.
BioPorto is headquartered in Hellerup, Denmark, and is listed on the NASDAQ Copenhagen stock exchange. [CPH: BIOPOR]
The NGAL Test is CE Marked and available for IVD use in the European Union. For Research Use Only in the United States.
Chief Executive Officer
Anthony Pare joined the Company in 2021. Mr. Pare has led product development, commercialization, marketing, operations, and business development in leading medical device and diagnostic companies for 25 years. Previously, he was the Chief Commercial Officer (CCO) at T2 Biosystems, a US Nasdaq-listed in vitro diagnostics company. He held the same role at Hemanext, a pre-commercial company marketing blood transfusion technology. Mr. Pare also held various leadership roles at Haemonetics, specializing in blood processing and diagnostic technologies. He actively participates on advisory boards and mentors startup medical technology companies in the Boston (US) area. Mr. Pare holds a Bachelor of Science in Marine Engineering and a Master’s of Engineering Administration from George Washington University (US).
Other directorships: None
Neil Goldman, CPA
Executive VP and Chief Financial Officer
Neil Goldman joined the Company in 2021. Mr. Goldman previously served as the Executive Vice President and Chief Financial Officer of Chembio Diagnostics, Inc. (Nasdaq:CEMI). He has been the Executive Vice President-Corporate Development and Chief Financial Officer at J.S. Held LLC, a construction consulting firm. He was the Global Finance Director for the Delphi Data Connectivity division of Delphi Corp. (now Aptiv plc, NYSE:APTV), an automotive supplier, following Delphi’s acquisition of Unwired Technology LLC (Unwired), a tier-1 global automotive electronics manufacturer and distributor, from a private equity firm. At Unwired, he was the Executive Vice President-Corporate Development and Chief Financial Officer, the Senior Vice President-Chief Operating and Financial Officer, and previously Chief Financial Officer. He also served as the Chief Financial Officer at EPPCO Enterprises, Inc., an importer and manufacturer of consumer and aftermarket products, and as a Senior Manager at Ernst & Young LLP and its successor Cap Gemini Ernst & Young LLC. He is a Certified Public Accountant and received a Bachelor of Science degree in Business-Accountancy from Miami University (Ohio, US).
Other directorships: Ohio Bridge Corp
EVP, Strategic Partnerships and General Manager, EMEA & APAC
Nis Kruse was appointed Executive Vice President of Strategic Partnerships and General Manager of EMEA & APAC in December 2022. Most recently, Nis served as SVP & Chief Commercial Officer at SSI Diagnostica A/S, an in vitro diagnostics company focusing on infectious diseases, where he delivered substantial topline growth during the COVID pandemic. Previously, operating in a US-based position, Nis was Executive Director of Global Precision Medicine at Merck & Co. responsible for commercial diagnostic strategy and commercial partner management related to Keytruda®. Earlier in his career, he held leadership roles in Copenhagen at Agilent Technologies, H. Lundbeck, and AstraZeneca. Nis holds Master’s and Bachelor’s degrees in Economics and Business Management from Aarhus University (Denmark).
Dr. Tabari Baker
VP Global Medical Affairs
Dr. Tabari Baker was appointed Vice President of Global Medical Affairs in February 2023. Dr. Baker most recently served as Director of Strategic Healthcare Partnerships at Roche Diagnostics, where he led cross-enterprise initiatives to communicate its diagnostic portfolio’s medical value throughout the patient journey. Also at Roche, Dr. Baker supported the launch of multiple companion diagnostic tests by providing clinical, scientific, and educational expertise as a Scientific Affairs Manager. Previously, Dr. Baker served in research and clinical liaison roles at Caris Life Sciences. Dr. Baker received his Ph.D. in Tumor Biology from Georgetown University. He earned an M.S. in Cancer Biology, Prevention, and Control from the University of the District of Columbia, and a B.S. in Chemistry from Morehouse College.
VP Quality Assurance and Regulatory Affairs
Asger was appointed Vice President of Quality Assurance and Regulatory Affairs at BioPorto in October 2021. With more than 20 years in the medical industry and a key focus on quality management. Asger provides a proven track record in the management of global quality organizations, strategic thinking, and execution. While at Agilent Technologies, Asger managed a team of 45 to provide ongoing quality support including management reviews, and audits (FDA, notifying bodies, internal and vendor). His experience also includes managing and supporting major IT implementations and a new IVD-R system for Complaints, Vigilance, NCR, and Post Market Surveillance. Asger holds a Bachelor of Science in Engineering from the DTU-Technical University of Denmark.
Ursula Klause, PhD
VP Research and Development
Ursula was appointed Vice President of Research and Development in December 2020. In this function, she leads a team of highly qualified and motivated scientists who are passionate about providing superior products to improve patients’ lives. She has a strong scientific background with more than 15 years in assay development and validation, system integration, biomarker discovery, and new technology assessments. Most recently, she served as a Senior Scientific Affairs Manager at Roche Diagnostics, where she managed and led industry-supported and industry-sponsored studies and served as point-of-contact for all customer off-label questions in regard to assays quality, standardization, and clinical utility. Ursula has a Master’s degree in Nutritional Sciences from the University of Bonn (Germany), and a PhD in Molecular Biology from the University of Cologne (Germany).
VP Global Marketing & US Commercialization
Jennifer Zonderman was appointed Vice President Global Marketing & US Commercialization in May 2019. Jennifer excels at leading sales organizations through change such as growth, new markets, product launches and team integrations. Focusing on process and system improvements and developing methods and teams to consistently achieve revenue goals is the key to her success. Jennifer’s sales career has spanned both medical and high tech; she has a Master’s Certificate from Wayne State and a Bachelor of Science from Alma College.
Dr. Prasad Devarajan
Senior Medical Director
With over 39 years of medical experience, Dr. Prasad Devarajan, MD, FAAP, FASN, joined the BioPorto team as Senior Medical Director in July 2022. He is a world-renown pediatric nephrologist at Cincinnati Children’s Hospital Medical Center in Ohio, where he is the Director of the Nephrology and Hypertension Division, Medical Director of the Stone Center, and Professor at the UC Department of Pediatrics. In addition, Dr. Devarajan is on the editorial and review boards of more than 20 journals and multiple US National Institutes of Health (NIH) study sections. He has authored more than 320 peer-reviewed journal articles, and his work has been continuously funded by NIH and several other foundations for over 30 years. He graduated from Lokmanya Tilak Municipal Medical College medical school.
Chairman of the Board
Mr. McDonough previously served as President and chief executive officer, of T2 BioSystems, Inc., a diagnostics company focused on the rapid detection of sepsis-causing pathogens. Mr. McDonough held several positions at Cytyc Corporation, a company focused on women’s health, and ultimately served as president of Cytyc Development Corporation. He also led the efforts that resulted in Cytyc’s acquisition by Hologic Inc. for over $6 billion. Mr. McDonough is currently a member of the board of directors at Solace Therapeutics and Cytrellis Biosystems. He earned his undergraduate degree in business from Stonehill College.
Other directorships: Cytrellis Biosystems, Inc. (Chair), Solace Therapeutics
Vice Chairman of the Board
Mr. Hardison most recently served as President, Chief Executive Officer, and as a member of the board of directors of Biotheranostics, Inc., an oncology-focused molecular diagnostics company which was acquired by Hologic Inc. Prior to Biotheranostics, he was the President and Chief Executive Officer and Director of Good Start Genetics, a molecular diagnostics company focused on reproductive health. Earlier in his career, he held many executive and senior management positions at a number of public companies including Laboratory Corporation of America and Quest Diagnostics, the two largest US clinical laboratories; Exact Sciences Corporation, a molecular diagnostics company; and SmithKline Beecham Corporation, a pharmaceutical company. He received his Bachelor of Arts in Political Science from the University of North Carolina, Chapel Hill.
Other directorships: HTG MOLECULAR, MDXHEALTH, Cytek Biosciences, Arima Genomics, YourBio, Genoescopy, Breath BioMedical
Michael S. Singer
Dr. Singer is currently Chairman and Chief Scientific Strategy Officer (CSO) and co-founder ofat Cartesian Therapeutics, Inc, a US biotech company that develops RNA-modified cell therapies. Prior to founding Cartesian, he was co-founder and CSO Chief Scientific Officer of two startups: Topokine Therapeutics and HealthHonors. Dr. Singer previously served as Director of Translational Medicine at the Novartis Institutes for Biomedical Research. He is a licensed physician and has been admitted to practice patent law. He serves as an adjunct professor at the Yale University School of Medicine. Dr. Singer completed residency at Harvard and holds a BS, MD, and PhD from Yale University.
Other directorships: Cartesian Therapeutics, Pykus Therapeutics, Anodyne Nanotech
Jan Leth Christensen
Mr. Christensen is an attorney-at-law and is currently a board member and partner at Lønberg & Leth Christensen Advokataktieselskab. He serves as Chairman of Havnens Bygningsudlejnings A/S, Best Ejendomme A/S, and Advokaternes Ejendomsadministration A/S, and is also a member of the executive management and/or the board of directors of several other companies and foundations. Mr. Christensen holds a Master’s degree in Law from the University of Copenhagen.
Other directorships: Murermester Willy Lynggard Petersens Familiefond, Rolf Krake Fonden, Hyldegårdsvej 40 A/S (Chair), WRP-Holding A/S, K/S Hørsvinget, Esplanaden Berlin Holding A/S, Havnen Lersø Parkallé 107 ApS (Chair), Lønberg & Leth Christensen Advokataktieselskab, Havnens Bygningsudlejning A/S (Chair), W. Lynggard Petersen Holding A/S, Søborgstræde 2 A/S (Chair), Best Ejendomme A/S (Chair), Advokaternes Ejendomsadministration A/S (Chair)
Peter Mørch Eriksen
Mr. Eriksen served as CEO of BioPorto from 2013 – 2021. He has spent more than 20 years in the MedTech/life science industries, including as CEO of Sense A/S and VP of Medtronic. From these positions, Mr. Eriksen has extensive experience in creating growth, restructuring and funding in technology-intensive and complex companies. He is an experienced leader with a record of business within the medical device industry and has broad experience selling and developing medical devices for both small and large MedTech companies. He has an accounting background, supplemented with management experience.
Other directorships: FluoGuide A/S (Chair), Monsenso A/S (Chair), Pharma Equity Group A/S (Chair), MyBlueLabel Compliance Services ApS (Chair), PME Holding ApS
Ninfa M. Saunders
Ms. Saunders has over 30 years of healthcare experience from the bedside as a clinical nurse specialist to C-suite roles, topping off her career as president and CEO of multi-hospital systems. As a healthcare executive, she maintained a laser focus on strategy, operations and people while optimizing patient care and enhancing the bottom line. She created innovative strategies that accelerated growth, strengthened operations, and saved lives. As CEO of Navicent Health, Ms. Saunders expanded the hospital’s reach in Georgia through mergers and acquisitions, partnerships, new service lines, and a strategic alliance with 30+ hospitals region-wide. In 2019, she orchestrated a merger with Charlotte-based Atrium Health to position Navicent for future growth and sustainability.
Other directorships: Quorum Health, T2 Biosystems, Medical Brain, Avia, Laudio, United States Health of Care, CVS/Aetna, Wesleyan College, Jefferson Health